The service provides detailed insights that can guide medication selection and dosing, ensuring safer and more effective therapies.

Agilus Diagnostics has launched its Pharmacogenomics Testing Service, which aims to help healthcare providers personalize treatments by understanding how a patient’s genetic makeup affects their response to medications. 

The service provides detailed insights that can guide medication selection and dosing, ensuring safer and more effective therapies.

Pharmacogenomics, the study of how genes affect an individual’s response to drugs, is increasingly considered valuable in managing complex medical conditions. 

This new service enables clinicians to tailor treatments to a patient's unique genetic profile, minimizing adverse reactions and enhancing treatment outcomes.

Dr Anand K, Managing Director and CEO of Agilus Diagnostics commented on the growing significance of pharmacogenomics in healthcare, especially as the global market for this technology is expected to reach $5.8 billion by 2028. 

He said, “As the Global Pharmacogenomics market is projected to reach $5.8 billion by 2028, we are excited to be at the forefront of this revolution in personalized medicine. With the increasing prevalence of diseases such as cancer, cardiovascular disorders, and diabetes, our new service harnesses state-of-the-art genome sequencing technologies to provide tailored treatment strategies that can significantly enhance patient outcomes."

The service uses whole exome sequencing to analyze 59 pharmacogenomic genes and 194 drugs, offering a data-driven approach to treatment. This process helps healthcare providers personalize medication plans to fit the patient’s genetic makeup, aiming for better outcomes and fewer side effects.

Dr Ravneet Kaur, Medical Geneticist at Agilus Diagnostics, said, “Far too many patients suffer from adverse drug reactions or ineffective treatments. Drug genomics offers a cost-saving solution by reducing hospital visits and readmissions through personalized treatment plans. Recent studies on the Indian population show that each individual carries eight pharmacogenomics variants that affect treatment selection and dosage. Addressing these genetic differences can significantly improve patient outcomes and ensure safer, more effective therapies."

The ability to match drugs and dosages to a patient’s genetic profile enhances treatment efficacy and reduces the risks associated with incorrect medication choices.

Mental Health Application

Pharmacogenomics is also showing promise in psychiatric care. Dr Samir Parikh, Chairperson of the Fortis National Mental Health Programme and Advisor to Agilus Diagnostics emphasised its importance in mental health treatments. 

He said, “By utilizing pharmacogenomic testing, psychiatrists can determine whether a patient carries specific genetic variants that affect drug metabolism. This invaluable information enables clinicians to select medications that are more likely to be effective and adjust dosages to minimize the risk of side effects. This personalized approach enhances symptom management and improves patient adherence to treatment.”

Agilus Diagnostics' new service covers various specialties, including oncology, cardiovascular disease, neurology, and pediatrics. 

With 32 genes tied to clinical annotations and dosing guidelines, the service is designed to support healthcare providers in personalizing treatments across various medical fields.

Stay tuned for more such updates on Digital Health News.